Search SEC
Fundamental Analysis
126 matches · 10756 cached companies
| Company | Fundamental | Momentum | Acceleration | Confidence | Revenue Growth | ROIC | FCF Growth | Op Margin Delta | Share Growth | Dividend Yield | Dividend Years | Payout Ratio | P/E | Signals |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience, Inc. | 84.4 | 61.7 | 37 | 91 | +25.17% | +117.43% | n/a | +40.37% | -0.87% | 0% | 0 | n/a | 14.88x | Gross margin expansion, Operating leverage, Net debt reduction, Share count reduction, Strong operating leverage2 warnings |
| ANABANAPTYSBIO, INC | 88 | 100 | 100 | 85 | +195.06% | n/a | n/a | +55.62% | -0.7% | 0% | 0 | n/a | n/a | Operating leverage, Share count reduction |
| TBPHTheravance Biopharma, Inc. | 86.6 | 100 | 100 | 85 | +35.11% | n/a | n/a | +101.38% | +1.86% | 0% | 0 | n/a | 16.35x | Operating leverage, Net debt reduction |
| ADMAADMA BIOLOGICS, INC. | 81.3 | 96.6 | 58 | 83 | +16.85% | +38.31% | n/a | +94.51% | -5.86% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, Share count reduction, Strong operating leverage4 warnings |
| HRMYHarmony Biosciences Holdings, Inc. | 77.3 | 44 | 44 | 86 | +31.28% | +43.62% | n/a | +13.95% | +0.39% | 0% | 0 | n/a | 11.73x | Net debt reduction1 warning |
| XBIOXenetic Biosciences, Inc. | 80.9 | 100 | 100 | 78 | +26.16% | n/a | n/a | +383.17% | +48.78% | 0% | 0 | n/a | n/a | Operating leverage, Net debt reduction1 warning |
| KRYSKrystal Biotech, Inc. | 80.6 | 100 | 100 | 77 | +49.33% | +24.15% | n/a | n/a | +2.63% | 0% | 0 | n/a | n/a | Operating leverage, ROIC expansion, Net debt reduction, Strong operating leverage |
| PUREPURE BIOSCIENCE, INC. | 68.2 | 100 | 100 | 90 | +15.41% | n/a | n/a | +122.86% | -0.92% | 0% | 0 | n/a | n/a | Operating leverage, Net debt reduction, Share count reduction1 warning |
| PRCTPROCEPT BioRobotics Corp | 65.9 | 100 | 90.3 | 91 | +50.89% | -27.54% | n/a | +93.04% | +3.92% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction |
| ABUSArbutus Biopharma Corp | 62.9 | 100 | 100 | 91 | +2,909.09% | +145.09% | n/a | +272.61% | +3.55% | 0% | 0 | n/a | n/a | Operating leverage, Net debt reduction |
| XERSXeris Biopharma Holdings, Inc. | 69.2 | 100 | 100 | 83 | +58.13% | +12.16% | n/a | +153.29% | +13.37% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction1 warning |
| CSTLCASTLE BIOSCIENCES INC | 59 | 39.3 | 39.6 | 91 | +6.8% | -10.75% | n/a | +36.38% | +6.26% | 0% | 0 | n/a | n/a | Net debt reduction3 warnings |
| NBIXNEUROCRINE BIOSCIENCES INC | 68.7 | 63.8 | 63.8 | 77 | +41.55% | +22.84% | n/a | -2.23% | +1.66% | 0% | 0 | n/a | 22.63x | Operating leverage, Strong operating leverage3 warnings |
| BTCYBIOTRICITY INC. | 62.4 | 100 | 100 | 84 | +20.79% | n/a | n/a | n/a | -4.69% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, Share count reduction1 warning |
| PLXProtalix BioTherapeutics, Inc. | 67.8 | 100 | 100 | 77 | +92.42% | +70.46% | n/a | +158.55% | +7.76% | 0% | 0 | n/a | 9.09x | Gross margin expansion, Operating leverage, Net debt reduction2 warnings |
| BDSXBIODESIX INC | 68.8 | 100 | 100 | 75 | +36.82% | -55.85% | n/a | +108.46% | +41.04% | 0% | 0 | n/a | n/a | Operating leverage, ROIC expansion, Net debt reduction2 warnings |
| MTNBMatinas BioPharma Holdings, Inc. | 60.3 | 100 | 60 | 86 | +96.93% | -397.41% | n/a | +6,033.87% | -98% | 0% | 0 | n/a | n/a | Operating leverage, Share count reduction2 warnings |
| BIOEBio Essence Corp | 65.5 | n/a | n/a | 78 | +377.37% | n/a | n/a | +123.94% | n/a | 0% | 0 | n/a | n/a | Gross margin expansion, Net debt reduction |
| BOLTBolt Biotherapeutics, Inc. | 55.6 | 100 | 60 | 91 | +10.06% | -1,724.06% | n/a | +437.3% | -11.81% | 0% | 0 | n/a | n/a | Operating leverage, Share count reduction1 warning |
| ABVCABVC BIOPHARMA, INC. | 58.9 | 100 | 100 | 83 | +5,042.66% | -40.18% | n/a | +13,798.36% | +138.87% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction2 warnings |
| ECOCABVC BIOPHARMA, INC. | 58.9 | 100 | 100 | 83 | +5,042.66% | -40.18% | n/a | +13,798.36% | +138.87% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction2 warnings |
| RGBPRegen BioPharma Inc | 60.5 | 0 | 0 | 79 | -0.13% | n/a | n/a | +249.93% | +2,755.78% | 0% | 0 | n/a | n/a | Net debt reduction3 warnings |
| RGBPPRegen BioPharma Inc | 60.5 | 0 | 0 | 79 | -0.13% | n/a | n/a | +249.93% | +2,755.78% | 0% | 0 | n/a | n/a | Net debt reduction3 warnings |
| TECHBIO-TECHNE Corp | 47.2 | 36.9 | 35.1 | 100 | +5.56% | +8.24% | -23.13% | -9.97% | -2.01% | 0.44% | 19 | 33.38% | 76.06x | Gross margin expansion, Net debt reduction, Share count reduction3 warnings |
| STROSUTRO BIOPHARMA, INC. | 60.5 | 100 | 100 | 76 | +51.32% | n/a | n/a | +32.11% | +98.12% | 0% | 0 | n/a | n/a | Operating leverage, Net debt reduction1 warning |
1-25 of 126